Compare MAA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAA | RLAY |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | MAA | RLAY |
|---|---|---|
| Price | $134.02 | $10.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $152.95 | $15.75 |
| AVG Volume (30 Days) | 984.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $2.85 | $19.96 |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $35.71 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $125.75 | $1.78 |
| 52 Week High | $173.38 | $9.54 |
| Indicator | MAA | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 69.98 |
| Support Level | $130.50 | $2.99 |
| Resistance Level | $136.83 | N/A |
| Average True Range (ATR) | 2.75 | 0.66 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 41.34 | 62.92 |
Mid-America Apartment Communities Inc is a multifamily-focused, self-administered and self-managed real estate investment trust. The company owns, operates, acquires and selectively develops apartment communities located in the Southeast, Southwest and Mid-Atlantic regions of the U.S. Its business objectives are to generate a sustainable, stable and increasing cash flow that will fund its dividends and distributions through all parts of the real estate investment cycle. It operates in two segments, Same Store and Non-Same Store and Other. The majority of the revenue is derived from Same Store segment.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).